化学性质
| Storage | Store at -20°C |
| M.Wt | 584.11 |
| Cas No. | 289715-28-2 |
| Formula | C32H34ClN7O2 |
| Synonyms | CB-300919;CB300919 |
| Solubility | Soluble in DMSO |
| Chemical Name | 4-[[7-chloro-3-methyl-2-[(4-methylpiperazin-1-yl)methyl]-4-oxoquinazolin-6-yl]methyl-prop-2-ynylamino]-N-(pyridin-3-ylmethyl)benzamide |
| Canonical SMILES | CN1CCN(CC1)CC2=NC3=CC(=C(C=C3C(=O)N2C)CN(CC#C)C4=CC=C(C=C4)C(=O)NCC5=CN=CC=C5)Cl |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
资料参考
CB 300919 is a potential therapy for ovarian cancer. Preclinical data showed that this quinazoline-based compound CB 300919 has a continuous exposure (96 h) growth inhibition IC50 value of 2 nM in human CH1 ovarian tumor xenograft.
